Heart fat drug may boost ablation success in AF patients
NCT ID NCT07331727
First seen Jan 12, 2026 · Last updated May 24, 2026 · Updated 24 times
Summary
This study tests whether dapagliflozin, a drug typically used for diabetes, can help prevent atrial fibrillation from coming back after a heart procedure called catheter ablation. The trial includes 280 adults with persistent AF and increased fat around the heart, but without diabetes or heart failure. Participants will take the drug or a placebo around the time of their ablation to see if it reduces irregular heart rhythms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shanghai Chest Hospital
Shanghai, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.